Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease-Reference-Cited by-同舟云学术

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease

Published:2020-02-01 Issue:2 Volume:77 Page:199
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Wessels Alette M.¹,Tariot Pierre N.²,Zimmer Jennifer A.¹,Selzler Katherine J.¹,Bragg Sonja M.¹,Andersen Scott W.¹,Landry John¹,Krull James H.¹,Downing AnnCatherine M.¹,Willis Brian A.¹,Shcherbinin Sergey¹,Mullen Jamie³⁴,Barker Peter³,Schumi Jennifer³,Shering Craig³,Matthews Brandy R.¹,Stern Robert A.⁵,Vellas Bruno⁶,Cohen Sharon⁷,MacSweeney Emer⁸,Boada Mercè⁹¹⁰,Sims John R.¹

Affiliation:

1. Eli Lilly and Company, Indianapolis, Indiana

2. Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix

3. AstraZeneca, Waltham, Massachusetts, and Gaithersburg, Maryland

4. Now retired

5. Alzheimer’s Disease Center, Boston University School of Medicine, Boston, Massachusetts

6. Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Unités Mixtes de Recherche Institut National de la Santé et de la Recherche Médicale 1027, Université Toulouse III–Paul Sabatier, Toulouse, France

7. Toronto Memory Program, Toronto, Ontario, Canada

8. Re:Cognition Health, London, United Kingdom

9. Research Center and Memory Clinic, Fundació Alzheimer Centre Educacional, Institut Català de Neurociències Aplicades, Barcelona–Universitat Internacional de Catalunya, Barcelona, Spain

10. Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain

Publisher

American Medical Association (AMA)

Subject

Clinical Neurology

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2755347/jamaneurology_wessels_2019_oi_190094.pdf

Reference32 articles.

1. Epidemiology of Alzheimer disease.;Reitz;Nat Rev Neurol,2011

2. Alzheimer’s disease.;Masters;Nat Rev Dis Primers,2015

3. Pathogenesis of Alzheimer’s disease: molecular and cellular mechanisms [in French].;Govaerts;Rev Med Liege,2007

4. Intracellular amyloid-ß in Alzheimer’s disease.;LaFerla;Nat Rev Neurosci,2007

5. AZD3293: pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer’s disease.;Cebers;J Alzheimers Dis,2017

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MnCoFe-LDH/Ni-MOF nanocomposite-coated hollow fiber membrane for solid phase extraction of amaranth dye from water and food samples followed by spectrophotometric analysis;Journal of Molecular Liquids;2024-02

2. Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups;Neurology;2024-01-23

3. Novel therapeutic approaches for targeting Alzheimer’s disease;Alzheimer's Disease and Advanced Drug Delivery Strategies;2024

4. Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2024-01

5. Targets, trials and tribulations in Alzheimer therapeutics;European Journal of Pharmacology;2024-01